Cost considerations in the pharmacological prevention and treatment of stroke

PharmacoEconomics

Volumn 11, Issue 5, 1997, Pages 408-418

  Alexandrov, Andrei V ^a,b   Smurawska, Liliana T ^a   Bartle, William ^a   Oh, Paul ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; HEPARIN; TICLOPIDINE; WARFARIN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE;

EID: 0030964949     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711050-00004     Document Type: Review

References (53)

1. American Heart Association. 1992 Heart and stroke facts. Dallas: American Heart Association, 1992
2. Lanska DJ, Kryscio R. Geographic distribution of hospitalization rates, case fatality, and mortality from stroke in the United States. Neurology 1995; 45: 634-40
3. Emanuel EJ, Emanuel LL. The economics of dying - the illusion of cost savings at the end of life. N Engl J Med 1994; 330: 540-4
4. Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertension 1991; 9: 199-208
5. Rocella EJ, Lenfant C. Considerations regarding the cost and effectiveness of public and patient education programmes. J Hum Hypertens 1992; 6: 463-7
6. Gorelick PB. Stroke prevention: an opportunity for efficient utilization of health care resources during the coming decade. Stroke 1994; 25: 220-4
7. Broderick JP, Phillips SJ, Whisnant JP, et al. Incidence rates of stroke in the eighties: the end of the decline in stroke? Stroke 1989; 20: 577-82
8. Wolf PA, D'Agostino RB, O'Neal A, et al. Secular trends in stroke incidence and mortality: the Framingham study. Stroke 1992; 23: 1551-5
9. North American Symptomatic Carotid Endaretectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high grade carotid stenosis. N Engl J Med 1991; 325: 445-53
10. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421-8
11. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-38
12. Weinstein MC, Stason WB. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732-7
13. Edelson JT, Weinstein MC, Tosteson ANA, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263: 408-13
14. Gafni A. On the costs of treating mild hypertension. J Gen Intern Med 1987; 2: 441-3
15. Millikan C, Futrell N. The strange story of aspirin and the prevention of stroke. J Stroke Cerebrovasc Dis 1995; 5: 248-54
16. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995; 332: 238-48
17. Solomon DH, Hart RG. Antithrombotic therapies for stroke prevention. Curr Opin Neurol 1994; 7: 48-53
18. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
19. Hass WK, Easton JD, Adams Jr HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-7
20. Oster G, Huse DM, Lacey MJ, et al. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke 1994; 25: 1149-56
21. Van Gijn J, Algra A. Ticlopidine, trials, and torture. Stroke 1994; 25: 1097-8
22. Warlow CP. Ticlopidine, a new antithrombotic drug: but is it better than aspirin for long-term use? J Neurol Neurosurg Psychiatry 1990; 53: 185-7
23. Bladin CF, Norris JW. Relative benefits of ticlopidine and aspirin [letter]. Stroke 1994; 25: 2290
24. Roderick J, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmacol 1993; 35: 219-26
25. Smurawska LT, Alexandrov AV, Bladin CF, et al. Cost of acute stroke care in Toronto, Canada. Stroke 1994; 25: 1628-31
26. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155: 469-73
27. Boston Area Anticoagulation Trial for Atrial Fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11
28. Stroke Prevention in Atrial Fibrillation investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84: 527-39
29. Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: 1839-45
30. European Atrial Fibrillation Trial Study group. Secondary stroke prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62
31. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989; II: 175-9
32. Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449-57
33. Gustafsson C, Asplund K, Britton M, et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457-60
34. Camarata PJ, Heros RC, Latchaw RE. Brain attack: the rationale for treating stroke as a medical emergency. Neurosurgery 1994; 34: 144-58
35. Rothrock JF, Hart RG. Antithrombolic therapy in cerebrovascular disease. Arch Intern Med 1991; 115: 885-95
36. Biller J, Love BB, Gordon DE. Antithrombotic therapy for ischemic cerebrovascular disease. Semin Neurol 1991; 11: 353-67
37. The International Stroke Trial Collaborative Group. The international stroke trial. Preliminary results part II: effects of heparin [abstract]. Stroke 1997; 28: 231
38. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983; 14: 668-76
39. Duke RJ, Bloch RF, Turpie AG, et al. Intravenous heparin for prevention of stroke progression in acute partial stable stroke. Ann Intern Med 1986; 105: 825-8
40. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588-93
41. Kay R, Woo J, Kreel L, et al. Stroke subtypes among Chinese living in Hong Kong: the Shatei stroke registry. Neurology 1992; 42: 985-7
42. Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1946; 335: 145-50
43. Donnan G, Davis SM, Chambers BR, et al. Trials of streptokinasc in severe acute ischaemic stroke [letter|. Lancet 1995; 345: 578-9
44. Multicentre Acute Stroke Trial - Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509-14
45. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-25
46. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7
47. Levy DE, Brott TG, Haley Jr EC, et al. Factors related to hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994; 25: 291-7
48. Pagan S, Morgenstern LB, Petitta A, et al. rt-PA Reduces length of stay and improves disposition following stroke [abstract]. Stroke 1997; 28: 272
49. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke: a population perspective. Diabetologia 1995; 38: 1061-8
50. Working Group on Emergency Brain Resuscitation. Emergency Brain Resuscitation. Ann Intern Med 1995; 122: 622-7
51. Langehorn P, Williams BO, Gilchrist W, et al. Do stroke units save lives? Lancet 1993; 342: 395-8
52. Jorgensen HS, Nakayama H, Raaschou HO, et al. The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of stay, and cost. A community-based study. Stroke 1995; 26: 1178-82
53. Baron JC, von Kummer R, del Zoppo GL. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke 1995; 26: 2219-21